Generics BulletinAeon Biopharma, which is working on developing a biosimilar version of Botox (onabotulinumtoxinA) in the US, has looked to rival developer Revance Therapeutics to recruit its new chief executive. Aeon
Generics BulletinViatris has agreed to pay up to $335m as part of a nationwide settlement resolving US opioid-related claims by states and local governments, marking the latest monetary relief set to be owed by a comp
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Start-Up Nosis Partners Its AI Pl
Generics BulletinViatris says its US generic glucagon 1mg/vial injectable is “actively being launched,” as the firm looks to deliver on its long-promised string of complex injectables going into a challenging 2025. Ne